FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2946936611> ?p ?o ?g. }

• W2946936611 endingPage "4583" @default.
• W2946936611 startingPage "4583" @default.
• W2946936611 abstract "4583 Background: NccRCC and ccRCCsd are aggressive tumors associated with poor prognosis and response to therapy. Combination strategies co-targeting VEGF signaling and inhibitory immune checkpoints are highly active in clear-cell renal cell carcinoma, but data is lacking in NccRCC and ccRCCsd. We conducted a multicenter, open-label, single arm phase II trial of atezolizumab plus bevacizumab in NccRCC and ccRCCsd. Methods: Patients with NccRCC and ccRCCsd ( > 20% sarcomatoid differentiation), and ECOG performance status of 0-2 were eligible. Prior systemic treatment was allowed with the exception of prior PD-1/PD-L1-directed therapy. Atezolizumab 1200mg and bevacizumab 15mg/kg were administered every 3 weeks until progression, unacceptable toxicity, or patient withdrawal. Primary endpoint was objective response rate (ORR) per RECIST 1.1. Exploratory biomarker analyses included PD-L1 expression on tumor (TC) and immune cells (IC), and spatial analysis of the immune infiltrate. Results: Sixty patients received at least 1 cycle of treatment, among whom 56 were evaluable for response (17 ccRCCsd and 39 NccRCC). ORR was 34% in the overall population, 53% in ccRCCsd and 26% in NccRCC. Median progression-free survival was 8.4 months (95%CI, 6.9-16.5). Baseline tumor tissue was available for 36 patients. TC PD-L1 expression ≥1% was associated with improved ORR (9/14, 64%) compared to patients with PD-L1 expression < 1% (4/20, 20%). Patients with TC PD-L1 expression ≥1% who experienced progressive disease as best response had shorter average distance between tumor cells and nearest neighboring immune cells at baseline. Further analysis of the immune tumor microenvironment on an expanded cohort, including IC PD-L1 expression and correlation with clinical outcomes, is ongoing and will be updated. Conclusions: The combination of atezolizumab plus bevacizumab is active in NccRCC and ccRCCsd. Candidate predictive biomarkers include PD-L1 expression in TC and topological analysis of the immune infiltrate. Clinical trial information: NCT02724878." @default.
• W2946936611 created "2019-06-07" @default.
• W2946936611 creator A5004554295 @default.
• W2946936611 creator A5007568796 @default.
• W2946936611 creator A5025864013 @default.
• W2946936611 creator A5039044023 @default.
• W2946936611 creator A5043368519 @default.
• W2946936611 creator A5045221892 @default.
• W2946936611 creator A5046795494 @default.
• W2946936611 creator A5052504518 @default.
• W2946936611 creator A5054221973 @default.
• W2946936611 creator A5055738663 @default.
• W2946936611 creator A5058325420 @default.
• W2946936611 creator A5061593455 @default.
• W2946936611 creator A5065568677 @default.
• W2946936611 creator A5073593424 @default.
• W2946936611 date "2019-05-20" @default.
• W2946936611 modified "2023-10-18" @default.
• W2946936611 title "Atezolizumab plus bevacizumab in non-clear cell renal cell carcinoma (NccRCC) and clear cell renal cell carcinoma with sarcomatoid differentiation (ccRCCsd): Updated results of activity and predictive biomarkers from a phase II study." @default.
• W2946936611 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.4583" @default.
• W2946936611 hasPublicationYear "2019" @default.
• W2946936611 type Work @default.
• W2946936611 sameAs 2946936611 @default.
• W2946936611 citedByCount "11" @default.
• W2946936611 countsByYear W29469366112019 @default.
• W2946936611 countsByYear W29469366112020 @default.
• W2946936611 countsByYear W29469366112023 @default.
• W2946936611 crossrefType "journal-article" @default.
• W2946936611 hasAuthorship W2946936611A5004554295 @default.
• W2946936611 hasAuthorship W2946936611A5007568796 @default.
• W2946936611 hasAuthorship W2946936611A5025864013 @default.
• W2946936611 hasAuthorship W2946936611A5039044023 @default.
• W2946936611 hasAuthorship W2946936611A5043368519 @default.
• W2946936611 hasAuthorship W2946936611A5045221892 @default.
• W2946936611 hasAuthorship W2946936611A5046795494 @default.
• W2946936611 hasAuthorship W2946936611A5052504518 @default.
• W2946936611 hasAuthorship W2946936611A5054221973 @default.
• W2946936611 hasAuthorship W2946936611A5055738663 @default.
• W2946936611 hasAuthorship W2946936611A5058325420 @default.
• W2946936611 hasAuthorship W2946936611A5061593455 @default.
• W2946936611 hasAuthorship W2946936611A5065568677 @default.
• W2946936611 hasAuthorship W2946936611A5073593424 @default.
• W2946936611 hasConcept C121608353 @default.
• W2946936611 hasConcept C126322002 @default.
• W2946936611 hasConcept C143998085 @default.
• W2946936611 hasConcept C203092338 @default.
• W2946936611 hasConcept C2775949291 @default.
• W2946936611 hasConcept C2776694085 @default.
• W2946936611 hasConcept C2777472916 @default.
• W2946936611 hasConcept C2777701055 @default.
• W2946936611 hasConcept C2777802072 @default.
• W2946936611 hasConcept C2778560582 @default.
• W2946936611 hasConcept C2780030458 @default.
• W2946936611 hasConcept C2781278892 @default.
• W2946936611 hasConcept C2908647359 @default.
• W2946936611 hasConcept C29730261 @default.
• W2946936611 hasConcept C31760486 @default.
• W2946936611 hasConcept C535046627 @default.
• W2946936611 hasConcept C71924100 @default.
• W2946936611 hasConcept C99454951 @default.
• W2946936611 hasConceptScore W2946936611C121608353 @default.
• W2946936611 hasConceptScore W2946936611C126322002 @default.
• W2946936611 hasConceptScore W2946936611C143998085 @default.
• W2946936611 hasConceptScore W2946936611C203092338 @default.
• W2946936611 hasConceptScore W2946936611C2775949291 @default.
• W2946936611 hasConceptScore W2946936611C2776694085 @default.
• W2946936611 hasConceptScore W2946936611C2777472916 @default.
• W2946936611 hasConceptScore W2946936611C2777701055 @default.
• W2946936611 hasConceptScore W2946936611C2777802072 @default.
• W2946936611 hasConceptScore W2946936611C2778560582 @default.
• W2946936611 hasConceptScore W2946936611C2780030458 @default.
• W2946936611 hasConceptScore W2946936611C2781278892 @default.
• W2946936611 hasConceptScore W2946936611C2908647359 @default.
• W2946936611 hasConceptScore W2946936611C29730261 @default.
• W2946936611 hasConceptScore W2946936611C31760486 @default.
• W2946936611 hasConceptScore W2946936611C535046627 @default.
• W2946936611 hasConceptScore W2946936611C71924100 @default.
• W2946936611 hasConceptScore W2946936611C99454951 @default.
• W2946936611 hasIssue "15_suppl" @default.
• W2946936611 hasLocation W29469366111 @default.
• W2946936611 hasOpenAccess W2946936611 @default.
• W2946936611 hasPrimaryLocation W29469366111 @default.
• W2946936611 hasRelatedWork W2269916035 @default.
• W2946936611 hasRelatedWork W2541318045 @default.
• W2946936611 hasRelatedWork W2560684296 @default.
• W2946936611 hasRelatedWork W2898246178 @default.
• W2946936611 hasRelatedWork W2900403924 @default.
• W2946936611 hasRelatedWork W2946936611 @default.
• W2946936611 hasRelatedWork W3170784747 @default.
• W2946936611 hasRelatedWork W4281653420 @default.
• W2946936611 hasRelatedWork W4291555108 @default.
• W2946936611 hasRelatedWork W4313045766 @default.
• W2946936611 hasVolume "37" @default.
• W2946936611 isParatext "false" @default.
• W2946936611 isRetracted "false" @default.
• W2946936611 magId "2946936611" @default.
• W2946936611 workType "article" @default.